Heart Views

: 2020  |  Volume : 21  |  Issue : 2  |  Page : 97--103

PCSK9 monoclonal antibodies: An overview

Rasha Kaddoura1, Bassant Orabi1, Amar M Salam2 
1 Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
2 Department of Cardiology, Al Khor Hospital, Hamad Medical Corporation, Doha, Qatar

Correspondence Address:
Dr. Rasha Kaddoura
Heart Hospital, Hamad Medical Corporation, Doha

PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C goal attainment. The commercially available PCSK9 monoclonal antibodies, alirocumab and evolocumab, have demonstrated reductions in major adverse cardiovascular events such as myocardial infarction, stroke, unstable angina, and the need for coronary revascularization but not mortality. PCSK9 monoclonal antibodies have demonstrated a favorable safety profile. The most reported side effects are mild injection site with no causal relationship proven between the inhibition of PCSK9 and neurocognitive or glycemic adverse events. In this overview, the efficacy and safety of PCSK9 monoclonal antibodies in the treatment of primary and familial hypercholesterolemia will be discussed.

How to cite this article:
Kaddoura R, Orabi B, Salam AM. PCSK9 monoclonal antibodies: An overview.Heart Views 2020;21:97-103

How to cite this URL:
Kaddoura R, Orabi B, Salam AM. PCSK9 monoclonal antibodies: An overview. Heart Views [serial online] 2020 [cited 2023 Oct 3 ];21:97-103
Available from: https://www.heartviews.org/article.asp?issn=1995-705X;year=2020;volume=21;issue=2;spage=97;epage=103;aulast=Kaddoura;type=0